According to our previous work, daily systemic administration of DNase I at the dose of 50 μg·per mouse per·day for 3 weeks provides meaningful suppression of primary tumor growth and metastasis development in subcutaneous and metastatic models of MC38 murine colon adenocarcinoma in C57BL/6 mice as well as in subcutaneous HCT116 human colorectal carcinoma and human Huh7 liver carcinoma models in NU/J mice [23]. This evidence concerns the gene DNASE1 and colon adenocarcinoma.